Page 27 - FLIPBOOK

Degarelix showed a 56% lower risk of a CV event or death during 1st year of

treatment in men with pre-existing CVD compared to LHRH agonists.

Risk reduction of CV events or death after the first year
of treatment in men with pre-existing CVD (n=708) The absolute risk reduction after the
first year was 8.2%, which yielded a
number needed to treat to avoid
1 CV event or death of 12
56% relative
risk reduction
CV event or death (%)

(HR: 0.44; 95%
CI, 0.26–0.74;
p=0.002)

GnRH agonist Degarelix
(n=254) (n=463)

CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; GnRH, gonadotropin-releasing hormone; HR,
hazard ratio

Albertsen PC et al. Eur Urol 2014;65:565-73.